Eli Lilly Stock Just Got Even Sweeter. Here’s Why It’s Worth Buying Now monthlywealthstream
According to a sneak peek of the data from one of Eli Lilly‘s (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk, (NYSE: NVO) and it isn’t the first time. Here’s why the stock is worth investing in even more than before. […]